Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)

摘要

The present invention concerns compositions and methods of use of antibodies or antibody fragments that bind to an epitope located within the second cysteine-rich domain (Cys2, amino acid residues 1575-1725) of MUC5AC. The antibodies bind with high specificity and selectivity to pancreatic cancer and are of use for therapy, detection and/or diagnosis of pancreatic cancer. In preferred embodiments, therapeutic antibody may be conjugated to at least one therapeutic agent, such as 90Y. Both in vivo and in vitro detection of pancreatic cancer may be performed with the subject methods and compositions. Specific dosages of radiolabeled antibody and/or gemcitabine, of use in human pancreatic cancer patients, are disclosed herein.

主权项

1. A method of detecting or diagnosing pancreatic cancer comprising:
a) obtaining a fresh blood, serum, or plasma sample from an individual; b) removing an inhibitor of anti-MUC5AC antibody binding from the sample by organic phase extraction; and c) performing an immunoassay with an anti-MUC5AC antibody or antigen-binding fragment thereof that binds to an epitope located within the second cysteine-rich domain (Cys2, amino acid residues 1575-1725) of MUC5AC;wherein binding of the antibody is indicative of pancreatic cancer in the individual and the immunoassay can detect early stage pancreatic cancer.